GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (NAS:VERU) » Definitions » ROE %

Veru (VERU) ROE %

: -92.88% (As of Dec. 2023)
View and export this data going back to 1990. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Veru's annualized net income for the quarter that ended in Dec. 2023 was $-33.10 Mil. Veru's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $35.64 Mil. Therefore, Veru's annualized ROE % for the quarter that ended in Dec. 2023 was -92.88%.

The historical rank and industry rank for Veru's ROE % or its related term are showing as below:

VERU' s ROE % Range Over the Past 10 Years
Min: -188.32   Med: -27.47   Max: 14.2
Current: -188.32

During the past 13 years, Veru's highest ROE % was 14.20%. The lowest was -188.32%. And the median was -27.47%.

VERU's ROE % is ranked worse than
87.54% of 1364 companies
in the Biotechnology industry
Industry Median: -44.1 vs VERU: -188.32

Veru ROE % Historical Data

The historical data trend for Veru's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.88 -60.77 8.11 -71.50 -181.81

Veru Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -234.78 -471.54 -104.26 -160.65 -92.88

Competitive Comparison

For the Biotechnology subindustry, Veru's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veru ROE % Distribution

For the Biotechnology industry and Healthcare sector, Veru's ROE % distribution charts can be found below:

* The bar in red indicates where Veru's ROE % falls into.



Veru ROE % Calculation

Veru's annualized ROE % for the fiscal year that ended in Sep. 2023 is calculated as

ROE %=Net Income (A: Sep. 2023 )/( (Total Stockholders Equity (A: Sep. 2022 )+Total Stockholders Equity (A: Sep. 2023 ))/ count )
=-93.153/( (82.797+19.678)/ 2 )
=-93.153/51.2375
=-181.81 %

Veru's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-33.104/( (19.678+51.602)/ 2 )
=-33.104/35.64
=-92.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Veru  (NAS:VERU) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-33.104/35.64
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-33.104 / 8.564)*(8.564 / 65.295)*(65.295 / 35.64)
=Net Margin %*Asset Turnover*Equity Multiplier
=-386.55 %*0.1312*1.8321
=ROA %*Equity Multiplier
=-50.72 %*1.8321
=-92.88 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-33.104/35.64
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-33.104 / -33.392) * (-33.392 / -35.204) * (-35.204 / 8.564) * (8.564 / 65.295) * (65.295 / 35.64)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9914 * 0.9485 * -411.07 % * 0.1312 * 1.8321
=-92.88 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Veru ROE % Related Terms

Thank you for viewing the detailed overview of Veru's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Veru (VERU) Business Description

Traded in Other Exchanges
Address
2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
Executives
Mario Eisenberger director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Harry Fisch director, 10 percent owner 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Grace Hyun director 48 NW 25TH STREET, SUITE 102, MIAMI FL 33127
Mitchell Shuster Steiner director, 10 percent owner, officer: President and CEO 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
K Gary Barnette officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michele Greco officer: VP and CFO 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60654
Jesus Socorro director 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Todd Charles T Jr officer: CEO of FHC Division 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michael L Rankowitz director 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Robert Getzenberg officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elgar Peerschke director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Daniel Haines officer: CFO and COO 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
David R Bethune director THE FEMALE HEALTH COMPANY, 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60610
O B Parrish director, officer: Chairman/Chief Exec. Officer

Veru (VERU) Headlines

From GuruFocus